Apoptosis, chemoresistance, and breast cancer: Insights from the MCF-7 cell model system

Experimental Biology and Medicine

Volumn 228, Issue 9, 2003, Pages 995-1003

  Simstein, Rebecca ^a   Burow, Matthew ^a   Parker, Amanda ^a   Weldon, Christopher ^a   Beckman, Barbara ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Apoptosis; Ceramide; Chemoresistance; MCF 7 cells; Tumor necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 9; CYTOCHROME C; DNA; ESTROGEN RECEPTOR; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; FULVESTRANT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C INHIBITOR; PROTEIN P53; PROTEIN P55; RAF PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER RESISTANCE; CELL DEATH; CELL STRAIN MCF 7; CELL SURVIVAL; HUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0141864377     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020322800903     Document Type: Short Survey

References (81)

1. Goldstein LJ, Cianfrocca M, von Mehren M, Gradel T, Kilpatrick D, Vaders L, Smolenski-Burke S, Brady D, Vogel L. Breast cancer research. Fox Chase Cancer Center Scientific Report. Philadelphia: Fox Chase Cancer Center, pp158-162, 2000.
2. Russo J, Yang X, Hu Y, Bove B, Huang Y, Silva IDCG, Tahin Q, Wu Y, Higgy N, Zekri A, Russo I. Biological and molecular basis of human breast cancer. Frontiers Biosci 3:d944-d960, 1998.
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606, 1993.
4. American Cancer Society. Cancer Facts and Figures. American Cancer Society, Atlanta, GA, 1996.
5. Wu J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Anticancer Res 16:2233-2240, 1996.
6. Furth PA. Apoptosis and the development of breast cancer. In: Bowcock AM, Ed. Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics. New Jersey: Humana Press, pp171-180, 1999.
7. Debatin A-K. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett 112-113:41-48, 2000.
8. Shao Z-M, Li J, Wu J, Han Q-X, Shen Z-Z, Fontana JA, Barsky SH. Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis. Br J Cancer Res Treat 53:263-269, 1999.
9. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol/3-kinase/Akt-mediated activation of estrogen receptor α: A new model for anti-estrogen receptor resistance. J Biol Chem 276:9817-9824, 2001.
10. Levenson AS, Jordan CV. MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res 57:3071-3078, 1997.
11. Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409-1416, 1973.
12. Gooch JL, Yee D. Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett 144:31-37, 1999.
13. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS. Differences in susceptibility to tumor necrosis factor α-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 58:4940-4946, 1998.
14. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257, 1972.
15. Story M, Kodym R. Signal transduction during apoptosis: Implications for cancer therapy. Frontiers Biosci 3:d365-d375, 1998.
16. Liu Y-Y, Han T-Y, Giuliao AE, Ichikawa S, Hirabayashi Y, Cabot MC. Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-α-induced apoptosis. Exp Cell Res 252:464-470, 1999.
17. Fadeel B, Zhivotovsky B, Orrenius S. All along the watchtower: On the regulation of apoptosis regulators. FASEB J 13:1647-1657, 1999.
18. Deveraux QL, Reed JC. IAP family proteins: Suppressors of apoptosis. Genes Dev 13:239-252, 1999.
19. Reed JC. The surviving saga goes in vivo. J Clin Invest 108:965-969, 2001.
20. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 197:241-246, 2001.
21. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12:397-408, 2001.
22. Kaufamnn SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49, 2000.
23. Ameyar M, Atfi A, Zhenzi C, Stancou R, Shatrov V, Bettaieb A, Chouaib S. Analysis of human breast adenocarcinoma MCF-7 resistance to tumor necrosis factor-induced cell death. J Biol Chem 273:29002-29008, 1998.
24. Fulda S, Los M, Friesen C, Debatin K-M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 76:105-114, 1998.
25. Poulaki V, Mitsiades CS, Mitsiades N. The role of fas and fasL as mediators of anticancer chemotherapy. Drug Resist Updat 4:233-242, 2001.
26. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-y treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60:5673-5680, 2000.
27. Herrnring C, Reimer T, Jeschke U, Makovitzky J, Kruger K, Gerber B, Kabelitz D, Friese K. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 113:189-194, 2000.
28. Zyad A, Benard J, Tursz T, Clarke R, Chouaib S. Resistance to TNF-α and adriamycin in the human breast cancer MCF-7 cell line: Relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res 54:825-831, 1994
29. Longley DB, Boyer J, Allen WL, Latif T. Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 62:2644-2649, 2002.
30. Nakamoto T, Ingawa H, Takagi K, Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for nonresectable liver tumors. Anticancer Res 20:4087-4096, 2000.
31. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59:734-741, 1999.
32. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Bolding MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331-367, 1999.
33. Wallach D. Apoptosis. Placing death under control. Nature 388:123,125-126, 1997.
34. Hu S, Vncenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem 272:17255-17257, 1997.
35. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, et al. Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195, 1997.
36. Earnshow WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68:383-424, 1999.
37. Doman RK, Perez M, Danto NJ. JNK and p53 stress signaling cascades are altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis. J Interferon Cytokine Res 19:261-269, 1999.
38. Ameyar M, Shatrov V, Bouquet C, Capoulade C, Cai Z, Stancou R, Badie C, Haddada H, Chouaib S. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: Relationship with c-myc and Rb. Oncogene 18:5464-5472, 1999.
39. Egeblad M, Jaatela M. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells. Int J Cancer 86:617-625.
40. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911, 1999.
41. Herr I, Debatin K-M. Cellular stress response and apoptosis in cancer therapy. Blood 98:2603-2614, 2001.
42. Siemankowski LM, Morreale, Briehl MM. Antioxidant defenses in TNF-related MCF-7 cells: Selective increase in MnSOD. Free Radic Biol Med 26:919-924, 1999.
43. Kurokawa H, Kazuto N, Fukumoto H, Tomonari A, Suzuki T, Saijo N. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7 breast cancer cells. Oncology Rep 6:33-37, 1999.
44. Liang Y, Yan C, Schor NF. Apoptosis in the absence of caspase 3. Oncogene 20:6570-6578, 2001.
45. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357-9360, 1998.
46. WolfBB, Schuler M, Echeverri F, Green DR. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 274:30651-30656, 1999.
47. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 61:348-354, 2001.
48. Liu Y-Y, Han T-Y, Giuliano AE, Ichikawa S, Hirabayashi Y, Cabot MC. Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-α-induced apoptosis. Exp Cell Res 252:464-470, 1999.
49. Pettus BJ. Chalfant CE, Hannun YA. Ceramide in apoptosis: An overview and current perspectives. Biochim Biophys Acta 1585:114-125, 2002.
50. Gudz TI, Tserng K-Y, Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 272:24154-24158, 1997.
51. Basu A, Mohanty S, Sun B. Differential sensitivity of breast cancer cells to tumor necrosis factor-alpha: Involvement of protein kinase C. Biochem Biophys Res Commun 280:883-891, 2001.
52. Senchenkov A. Litvak DA, Cabot MC. Targeting ceramide metabolism: A strategy for overcoming drug resistance. J Natl Cancer Inst 93:347-357, 2001.
53. Cai Z, Bettaieb A, El Mahdani N, Legres LC, Stancou R, Masliah J, Chouaib S. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-α-mediated cytotoxicity. J Biol Chem 272:6918-6926, 1997.
54. Leung LK, Wang TTY. Paradoxical regulation of Bcl-2 family proteins by 17β-oestradiol in human breast cancer cells MCF-7. Br J Cancer 81:387-392, 1999.
55. Burow ME, Tang Y, Collins-Burow BM, Krajewski S, Reed JC, McLachlan JA, Beckman BS. Effects of environmental estrogens on tumor necrosis factor α-mediated apoptosis in MCF-7 cells. Carcinogenesis 20:2057-2061, 1999.
56. Vakkala M, Lahteenmaki K, Raunio H, Paako P, Soini Y. Apoptosis during breast carcinoma progression. Clin Cancer Res 5:319-324, 1999.
57. Tudor G, Aguilera A, Halverson DO, Liang ND, Sausville EA. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2, and Bcl-xL protein levels. Cell Death Differ 7:574-586, 2000.
58. Leung LK, Wang TTY. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat 55:73-83, 1999.
59. Gibson LF, Fortney J, Magro G, Ericson SG, Lynch JP, Landreth KS. Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. Breast Cancer Res Treat 55:107-117, 1999.
60. Berchem GJ, Bosseler M, Mine N, Avalosse B. Nanomolar range docetaxol treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 19:535-540, 1999.
61. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-xs sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55:2507-2510, 1995.
62. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 58:2134-2140, 1998.
63. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 93:463-471, 2001.
64. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anti-cancer agents. Science 290:989-992, 2000.
65. Campos L, Roualt JP, Sabido O. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091-3096, 1993.
66. Sakakura C, Sweeney EA, Shirihama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 67:101-105, 1996.
67. Suzuki K, Takahashi K. Anchorage-independent activation of mitogen-activated protein kinase through phosphatidylinositol-3 kinase by insulin-like growth factor I. Biochem Biophys Res Commun 272:111-115, 2000.
68. Xie W, Duan R, Safe S. Activation of adenosine deaminase in MCF-7 cells through IGF-estrogen receptor alpha crosstalk. J Mol Endocrinol 26:217-228, 2001.
69. Razzini G, Berrie CP, Vignati S, Briginni M, Mascetta G, Brancaccio A, Falasca M. Novel function PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J 14:1179-1187, 2000.
70. Nicholson KM, Anderson NG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14:381-395, 2002.
71. Gelfanov VM, Burgess GS, Litz-Jackson S, King AJ, Marshall MS, Nakshatri H, Boswell HS. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: Cooperation of akt with raf/erk leads to p65 nuclear factor κB-mediated antiapoptosis involving c-IAP2. Blood 98:2508-2517, 2001.
72. Toker A. Signaling through protein kinase C. Frontiers Biosci 3: dl134-dl147, 1998.
73. Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, McLachlan JA. PI3-K/AKT regulation of NF-κB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun 271:342-345, 2000.
74. Meng F, Liu L, Chin PC, D'Mello SR. AKT is a downstream target of NF-κB. J Biol Chem 277:29674-29680, 2002.
75. Burow ME, Collins-Burow BM, Weldon CB, Klippel A, McLachlan JA, Clejan S, Beckman BS. Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem 275:9628-9635, 2000.
76. Bours V, Bentires-Alj M, Hellin A-C, Viatour P, Robe P, Delhalle S, Benoit V, Merville M-P. Nuclear factor-κB, cancer, and apoptosis. Biochem Pharmacol 60:1085-1090, 2000.
77. Lin Y, Devin A, Rodriguez Y, Liu Z-G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 13:2514-2526, 1999.
78. Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, Reed JC, Merville MP, Bours V. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 20:805-813, 2001.
79. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS. NF-KB-mediated chemoresistance in breast cancer cells. Surgery 130:143-150, 2001.
80. Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, Liu A, Zhu Y, Davis N, et al. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappa B, and cyclic AMP response element binding with acquired resistance to Fasodex (ICI 182,780). Cancer Res 62:3428-3437, 2000.
81. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, et al. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132:293-301, 2002.